Protalix Cost Of Revenue from 2010 to 2025
| PLX Stock | USD 2.60 0.11 4.42% |
Cost Of Revenue | First Reported 1998-06-30 | Previous Quarter 8.4 M | Current Value 3.9 M | Quarterly Volatility 2.6 M |
Check Protalix Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protalix Biotherapeutics' main balance sheet or income statement drivers, such as Interest Expense of 1 M, Other Operating Expenses of 32.3 M or Operating Income of 4.1 M, as well as many indicators such as Price To Sales Ratio of 2.43, Dividend Yield of 0.0 or PTB Ratio of 3.0. Protalix financial statements analysis is a perfect complement when working with Protalix Biotherapeutics Valuation or Volatility modules.
Protalix | Cost Of Revenue |
Latest Protalix Biotherapeutics' Cost Of Revenue Growth Pattern
Below is the plot of the Cost Of Revenue of Protalix Biotherapeutics over the last few years. Cost of Revenue is found on Protalix Biotherapeutics income statement and represents the costs associated with goods and services Protalix Biotherapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities. It is Protalix Biotherapeutics' Cost Of Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protalix Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
| Cost Of Revenue | 10 Years Trend |
|
Cost Of Revenue |
| Timeline |
Protalix Cost Of Revenue Regression Statistics
| Arithmetic Mean | 12,504,975 | |
| Geometric Mean | 9,879,794 | |
| Coefficient Of Variation | 58.87 | |
| Mean Deviation | 6,122,262 | |
| Median | 10,873,000 | |
| Standard Deviation | 7,361,928 | |
| Sample Variance | 54.2T | |
| Range | 24.8M | |
| R-Value | 0.86 | |
| Mean Square Error | 14.7T | |
| R-Squared | 0.75 | |
| Significance | 0.000016 | |
| Slope | 1,335,839 | |
| Total Sum of Squares | 813T |
Protalix Cost Of Revenue History
About Protalix Biotherapeutics Financial Statements
Protalix Biotherapeutics investors use historical fundamental indicators, such as Protalix Biotherapeutics' Cost Of Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Protalix Biotherapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Cost Of Revenue | 24.3 M | 25.5 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Protalix Stock Analysis
When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.